Literature DB >> 17613235

Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia.

Gary A Rosenberg1, Yi Yang.   

Abstract

Cerebral ischemia causes cell swelling and breakdown of the blood-brain barrier (BBB). Cytotoxic edema results from energy failure, and vasogenic edema occurs when the blood vessels are damaged. Proteases and free radicals are the end result of a molecular injury cascade. Matrix metalloproteinases (MMPs) are a gene family of extracellular matrix-degrading enzymes that disrupt the BBB. Tight junction proteins (TJPs), occludin and claudin-5, which form the endothelial barrier, are vulnerable to attack by MMPs. Basal lamina proteins, such as fibronectin, laminin, and heparan sulfate, are also degraded by MMPs. Reperfusion injury leads to a biphasic opening of the BBB, with the early opening occurring several hours after the onset of reperfusion due to activation of the constitutive enzyme gelatinase A (MMP-2). This initial opening is transient and followed 24 to 48 hours later by more intense damage to the blood vessel, which is associated with the expression and activation of gelatinase B (MMP-9) and stromelysin-1 (MMP-3). Synthetic MMP inhibitors restore the early integrity of the BBB but are ineffective in the later opening. Because these inhibitors block MMPs involved in angiogenesis and neurogenesis, they also slow recovery. The challenge is to identify agents that will protect the BBB, blocking vasogenic edema without interfering with recovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613235     DOI: 10.3171/foc.2007.22.5.5

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  131 in total

1.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

Review 2.  Neurovascular unit: a focus on pericytes.

Authors:  Inês Sá-Pereira; Dora Brites; Maria Alexandra Brito
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

3.  Effect of propofol post-treatment on blood-brain barrier integrity and cerebral edema after transient cerebral ischemia in rats.

Authors:  Jae Hoon Lee; Hui Song Cui; Seo Kyung Shin; Jeong Min Kim; So Yeon Kim; Jong Eun Lee; Bon-Nyeo Koo
Journal:  Neurochem Res       Date:  2013-08-29       Impact factor: 3.996

4.  Blood cells and endothelial barrier function.

Authors:  Stephen F Rodrigues; D Neil Granger
Journal:  Tissue Barriers       Date:  2015-04-03

5.  Dl-3-n-butylphthalide Attenuates Spinal Cord Injury via Regulation of MMPs and Junction Proteins in Mice.

Authors:  Binbin Zheng; Yanjun Jin; Shuang Mi; Wei Xu; Xiangdong Yang; Zhenghua Hong; Zhangfu Wang
Journal:  Neurochem Res       Date:  2021-06-04       Impact factor: 3.996

6.  Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia.

Authors:  Yi Yang; Eduardo Candelario-Jalil; Jeffrey F Thompson; Eloy Cuadrado; Eduardo Y Estrada; Anna Rosell; Joan Montaner; Gary A Rosenberg
Journal:  J Neurochem       Date:  2009-10-15       Impact factor: 5.372

Review 7.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

Review 8.  Matrix metalloproteinases as therapeutic targets for stroke.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Brain Res       Date:  2015-04-25       Impact factor: 3.252

Review 9.  Traumatic brain injury, neuroinflammation, and post-traumatic headaches.

Authors:  Cynthia L Mayer; Bertrand R Huber; Elaine Peskind
Journal:  Headache       Date:  2013-07-08       Impact factor: 5.887

Review 10.  Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury.

Authors:  Xing-miao Chen; Han-sen Chen; Ming-jing Xu; Jian-gang Shen
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.